Skip to content

Clinical Implementation of Amyloid Neurodegeneration and Tau testing in Primary Care.

Clinical Implementation of Amyloid Neurodegeneration and Tau testing in Primary Care. - CANTATE-PC

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON56307
Enrollment
400
Registered
2023-06-28
Start date
2023-11-24
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AD Alzheimers disease Alzheimers disease

Interventions

None listed

Sponsors

Vrije Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Present to primary care with cognitive complaints or behavioral change. Either the patient him/herself, a caretaker / relative, the GP or elderly care physician needs to be concerned. 2) Adequate fluency in Dutch to understand the informed consent and complete questionnaires.

Exclusion criteria

Exclusion criteria: 1) Age under 50. 2) Alcohol / drug abuse to such an extent that treatment would be advisable.

Design outcomes

Primary

MeasureTime frame
1)Working diagnosis of the general practitioner in terms of: - Disease stage - Suspected etiology 2) Plasma biomarkers for Alzheimer's disease.

Secondary

MeasureTime frame
1) Patient management decisions at baseline. 2) Working diagnosis (defined as etiology and diseases stage) after 6 months. 3) Patient/caregiver-reported cognitive complaints. 4) Global cognitive functioning. 5) Impairment in daily living. 6) Qualitative evaluation of unmet needs in primary care that can be fulfilled by an AD blood test as defined by the practitioner.

Countries

Netherlands

Contacts

Public ContactT. Claessen

Vrije Universiteit

CANTATE@amsterdamumc.nl020 444 8548

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)